The most promising new antibiotic for Crohn's disease is not coming from a major pharmaceutical company. It is a narrow-spectrum molecule called Enterololin, and its global development rights now belong to a small Canadian biotech startup named Stoked Bio [GlobeNewswire, Feb 2026]. This exclusive license from McMaster University, secured in February 2026, is the first major external validation for the company's AI-assisted drug discovery engine, called MOSAIC. For patients with inflammatory bowel disease, the bet is that a more targeted therapy could avoid the broad-spectrum damage of current treatments. For Stoked Bio, it is the lead asset in a strategy to build a pipeline of patentable small-molecule drugs for resistant infections and cancers, taking them to the brink of human trials before partnering with larger biopharma players [stokedbio.com, Unknown].
A biology-first AI wedge
Stoked Bio's approach, born in the Stokes Lab at McMaster University, deliberately departs from the pure computational screens favored by some AI-native drug discovery firms. The MOSAIC platform is described as "biology-driven," meaning it starts with deep biological understanding of a disease target and uses AI to assist in identifying and optimizing compounds, not to generate them from scratch [Synapse Consortium, Unknown]. This focus on a narrower, more interpretable search space is intended to yield candidates with higher odds of clinical success and clearer intellectual property. The company's initial pipeline reportedly includes four novel programs targeting antimicrobial resistance and glioblastoma, with the Enterololin license for Crohn's representing a strategic expansion into immunology [Perplexity Sonar Pro, Unknown].
The team and the seed capital
Leadership combines academic roots with translational experience. Co-founder Jonathan Stokes provides the scientific foundation from McMaster, while CEO Jeff Skinner, whose background includes business development roles in life sciences, leads the company's operational and partnering strategy [stokedbio.com, Unknown]. The team also includes Denise Catacutan, listed in a business development capacity [LinkedIn, Unknown]. This academic spinout structure is a common, and often effective, model for early-stage biotech, providing strong IP and scientific credibility. The company is a graduate of the Creative Destruction Lab accelerator and has closed a seed financing round, though the amount and lead investors have not been publicly disclosed [BioSpace, Unknown]. The capital is presumably directed at advancing Enterololin and the MOSAIC platform's other programs through preclinical development.
| Metric | Value |
|---|---|
| Enterololin License | 1 Exclusive Global Asset |
| Reported Pipeline Programs | 4 Infections & Cancer |
| Disclosed Funding Round | 1 Seed |
Navigating the preclinical valley
Every biotech startup at this stage faces a steep, expensive path. The risks for Stoked Bio are not unique, but they are formidable.
- Technical validation. The MOSAIC platform's true differentiation and success rate will only be proven as its candidates advance. Peer-reviewed publication of its methodology and results will be a critical milestone for scientific and investor credibility.
- Funding runway. With an undisclosed seed round, the public cannot gauge the company's cash position. Advancing even one asset to an Investigational New Drug (IND) application typically requires tens of millions of dollars and several years. Securing a sizable Series A or a strategic partnership will be a near-term necessity.
- The partnering motion. Stoked Bio's stated model is to develop assets to IND-readiness for pharma partners [stokedbio.com, Unknown]. This requires not only compelling data but also a business development engine capable of engaging with large, slow-moving potential licensees in a crowded field of AI-discovered assets.
The standard of care for moderate-to-severe Crohn's disease today involves a difficult trade-off. Biologics like anti-TNF agents can be effective but are expensive, administered via injection or infusion, and carry risks of serious infection. Broad-spectrum antibiotics are sometimes used but disrupt the entire gut microbiome with significant side effects. Enterololin represents a potential third path: a small-molecule, orally available antibiotic designed to selectively target a specific gut bacterium linked to inflammation, potentially offering efficacy with a better safety profile [MIT News, 2025]. This is the patient population Stoked Bio is ultimately aiming to serve, and the high unmet need is what makes the preclinical risk worth taking.
Sources
- [GlobeNewswire, Feb 2026] Stoked Bio Secures Exclusive Global License to Develop a Promising New Therapy for Crohn’s Disease | https://www.globenewswire.com/news-release/2026/02/18/3240347/0/en/stoked-bio-secures-exclusive-global-license-to-develop-a-promising-new-therapy-for-crohn-s-disease.html
- [stokedbio.com, Unknown] What We Do - stokedbio.com | https://stokedbio.com/what-we-do/
- [Synapse Consortium, Unknown] How Stoked Bio is Using AI to Fight Deadly Diseases | https://synapseconsortium.com/how-stoked-bio-is-using-ai-to-fight-deadly-diseases/
- [stokedbio.com, Unknown] Team - stokedbio.com | https://stokedbio.com/team/
- [LinkedIn, Unknown] Denise Catacutan - stoked bio | https://www.linkedin.com/in/denise-catacutan-b380a1189/
- [BioSpace, Unknown] Stoked Bio Announces the Closing of Seed Financing Round | https://www.biospace.com/press-releases/stoked-bio-announces-the-closing-of-seed-financing-round
- [MIT News, 2025] AI maps how a new antibiotic targets gut bacteria | https://news.mit.edu/2025/ai-maps-how-new-antibiotic-targets-gut-bacteria-1003
- [Creative Destruction Lab, Unknown] Stoked Bio - Creative Destruction Lab | https://creativedestructionlab.com/companies/stoked-bio/